Core Insights - PayPoint Plc reported an encouraging start to the financial year, with confidence in achieving a £100 million EBITDA target and long-term growth goals through FY28 [2][5] Group and Divisional Highlights - Group net revenue increased by 7.5% to £42.2 million compared to £39.2 million in Q1 FY25, driven by strong performances in E-commerce, Payments and Banking, and Love2shop divisions [5] - Shopping divisional net revenue rose by 0.6% to £16.5 million, with service fee net revenue increasing by 7.8% to £5.7 million due to growth in PayPoint One/Mini sites [6] - E-commerce divisional net revenue surged by 20.8% to £5.1 million, with parcel transactions growing by 19.4% to 38.2 million [7] - Payments and Banking divisional net revenue increased by 4.9% to £12.8 million [7] - Love2shop divisional net revenue grew by 21.7% to £7.8 million [8] Growth Initiatives - The company signed a new 3-year agreement with InPost/Yodel to enhance parcel delivery services and is preparing for increased parcel volumes through a partnership with Royal Mail [3] - In Open Banking and Digital payments, new contracts were secured with Thirteen Group and the Department for Work and Pensions, contributing to a growing business pipeline [3] - Local Banking initiatives are set to launch consumer deposits with the first High Street Bank in August 2025 [3] Financial Performance - The Group's net corporate debt as of 30 June 2025 was £109.6 million, an increase from £97.4 million as of 31 March 2025 [11] - The Board declared an increased final dividend of 19.6 pence per share, up from 19.2 pence per share in the previous year [12] - An enhanced share buyback program commenced on 1 July 2025, aiming to return at least £30 million per annum to shareholders [13][14] Market Conditions - The company is actively monitoring consumer uncertainty and cautious behavior in various markets, maintaining tight cost discipline while executing growth plans [4]

Core Insights - Scatec ASA has achieved financial closure for its 142 MW solar PV plant in Minas Gerais, Brazil, with an expected Commercial Operation Date in the first half of 2026 [1][2][3] Financing Details - The non-recourse project financing totals BRL 150 million (USD 27 million), representing 30% of the total estimated capital expenditure of BRL 506 million (USD 91 million) [2] - Scatec has secured an additional EUR 25 million debt facility from Impact Fund Denmark to partially fund its equity share, bringing the total expected equity injection to BRL 201 million (USD 36 million) by COD [4] Project Management and Agreements - Scatec holds a 100% ownership stake in the solar project and plans to introduce equity partners post-COD to enhance value creation [5] - A 10-year power purchase agreement has been signed with Statkraft for approximately 75% of the expected power output, with the remainder to be sold under various term PPAs [4] Company Overview - Scatec is a prominent renewable energy solutions provider, with 6.2 GW of capacity in operation and under construction across five continents [6]

Group 1 - The core theme of the event held by Shanghai Zhenhua Heavy Industries Co., Ltd. (ZPMC) was "New Technologies, New Products, New Standards, New Achievements," focusing on advancements in smart port construction [1] - ZPMC showcased its innovative equipment, including a live demonstration of a "one-button" remote control for quay cranes, highlighting the impact of automation on port operations [2] - Company executives discussed ZPMC's commitment to delivering world-class equipment and contributing to international standards while addressing global market opportunities and challenges [3] Group 2 - ZPMC is recognized as the world's largest manufacturer of port machinery and a leading provider of automated terminal system solutions, with numerous world-first achievements [4] - The company actively participates in the formulation of international standards, aiming to integrate into the global innovation network and promote high-quality industry development [4]

Core Points - Sampo plc has announced a share buyback programme amounting to EUR 200 million to return excess capital generated in 2024 [1][2] - The buyback programme is set to commence on 7 August 2025 and will conclude no later than 31 October 2025, with a maximum repurchase of 30 million shares, representing 1% of total shares [3] - The shares will be repurchased at a price not exceeding the highest price paid in public trading on the day of repurchase or the average price over the preceding five trading days [4] Financial Management - The buyback is part of Sampo's capital management policy aimed at maintaining a strong but efficient balance sheet [2] - The repurchased shares will be cancelled, thereby reducing the capital of Sampo [6] - The programme is based on the authorization granted by the Annual General Meeting held on 23 April 2025 [6] Execution Details - Morgan Stanley has been appointed as the lead manager for the share buyback programme, making trading decisions independently [5] - The repurchases will be conducted in compliance with the EU Market Abuse Regulation [5] - Shares may also be acquired through accelerated bookbuilds (ABB) under certain conditions [4]

Core Insights - ONWARD Medical N.V. has appointed Lucas Buchanan as a non-executive member of its Board of Directors, enhancing its leadership team as it aims to grow its business and fulfill its mission to restore movement and function for individuals with spinal cord injuries and other movement disabilities [1][2] Company Overview - ONWARD Medical is a leading neurotechnology company focused on pioneering therapies to restore movement, function, and independence in individuals with spinal cord injuries (SCI) and other movement disabilities [4] - The company has developed ARC Therapy, which has received ten Breakthrough Device Designations from the US FDA, and its ARC-EX System is cleared for commercial sale in the US [4] - ONWARD is also working on an investigational implantable system called ARC-IM, which may include an implanted brain-computer interface (BCI) [4] Leadership and Expertise - Lucas Buchanan brings over 25 years of experience in commercialization, operations, business development, investing, and finance, having previously served as COO and CFO at Silk Road Medical, leading the company to its IPO in 2019 and subsequent acquisition by Boston Scientific in 2024 [2][6] - Buchanan is an active investor and currently serves on the boards of several medical technology companies, showcasing his extensive involvement in the healthcare sector [3][6] Strategic Vision - The appointment of Buchanan is seen as a strategic move to leverage his unique experiences as an operator and investor to help ONWARD Medical achieve its ambitions and deliver hope to millions affected by spinal cord injuries and movement disabilities [2][3]

Core Insights - Ringkjøbing Landbobank reported core earnings of DKK 1,580 million and a net profit of DKK 1,191 million for the first half of 2025, reflecting a 21% annual return on equity [1][4] - The bank's core income increased by 2% to DKK 2,090 million compared to the same period in 2024 [4] - The net profit per share rose by 6% to DKK 47.9 in the first half of 2025 [4] Financial Performance - Total core income for H1 2025 was DKK 2,090 million, up from DKK 2,051 million in H1 2024 [2] - Total expenses and depreciation increased to DKK 534 million from DKK 508 million in the previous year [2] - Core earnings before impairment charges were DKK 1,556 million, slightly up from DKK 1,543 million in H1 2024 [2] Impairment and Credit Quality - Impairment charges for loans were DKK 24 million, indicating strong credit quality, with no impairment charges recorded in Q2 2025 [4] - The bank's continued strong credit quality is highlighted by the low impairment charges [4] Customer Growth and Awards - The bank experienced a 9% growth in loans and an 8% increase in deposits, alongside a highly satisfactory increase in customer numbers [4] - Ringkjøbing Landbobank received the Financial Institution of the Year award for the 10th consecutive year in Q2 2025 [4] Future Outlook - The expectations for net profit for the full year 2025 have been adjusted upward to a range of DKK 2.0 - 2.35 billion [4]

Core Insights - Sampo Group reported strong financial results for the first half of 2025, with significant growth in gross written premiums and underwriting profits, driven by disciplined underwriting and efficiency gains [2][3][5] Financial Performance - Gross written premiums increased by 9% year-on-year to EUR 2,542 million in Q2 2025 and by 11% to EUR 6,242 million in the first half [3] - Insurance revenue, net, rose by 10% to EUR 2,264 million in Q2 and by 9% to EUR 4,452 million in the first half [3] - The underwriting result improved by 23% to EUR 393 million in Q2 and by 26% to EUR 729 million in the first half [3] - Net profit surged by 35% to EUR 417 million in Q2 and by 8% to EUR 703 million in the first half [3] - Operating EPS increased by 26% to EUR 0.16 in Q2 and remained stable at EUR 0.26 for the first half [3] Operational Efficiency - The combined ratio improved to 82.6% in Q2 and 83.6% in the first half, reflecting better underwriting margins and a favorable claims environment [3][5] - The risk ratio decreased to 56.8% in Q2 and 57.8% in the first half, while the cost ratio slightly increased to 25.9% in Q2 and 25.8% in the first half [3] Strategic Initiatives - Sampo announced a new EUR 200 million share buyback program, funded by capital generated in 2024 [5][16] - The outlook for the 2025 underwriting result has been raised to EUR 1,425–1,525 million, indicating an expected growth of 8–16% year-on-year [22] Market Position and Growth - The private operations in the Nordics and the UK showed strong premium growth of 9% and 13% respectively, supported by improved customer retention and digital sales [2][10][12] - Digital sales in the Commercial segment increased by 30% in the first half, indicating a shift towards online purchasing among SMEs [11] Leadership Transition - Torbjörn Magnusson announced his retirement as Group CEO, with Morten Thorsrud appointed as his successor effective from October 1, 2025 [20]

Core Insights - The company reported a net sales increase of 16% in H1 2025 compared to H1 2024, reaching DKK 154.9 billion, with an operating profit growth of 25% to DKK 72.2 billion [2][4] - Despite strong sales growth, the company has lowered its full-year outlook due to reduced growth expectations for GLP-1 treatments in the second half of 2025 [3][4] - The company is focusing on enhancing commercial execution and ensuring cost efficiencies while continuing to invest in future growth opportunities [3][4] Financial Performance - Net sales for H1 2025 were DKK 154,944 million, up from DKK 133,409 million in H1 2024, representing a 16% increase [2] - Operating profit rose to DKK 72,240 million, a 25% increase from DKK 57,780 million in the previous year [2] - Net profit increased by 22% to DKK 55,537 million from DKK 45,457 million [2] Sales Breakdown - Sales in US Operations increased by 16% in Danish kroner, positively impacted by gross-to-net sales adjustments, including a DKK 3 billion adjustment in Q2 2025 [4] - Sales in International Operations also grew by 16% in Danish kroner [4] - Sales within Diabetes and Obesity care rose by 16% to DKK 145.4 billion, driven by a 56% increase in Obesity care sales to DKK 38.8 billion [4] Research and Development - The company plans to advance subcutaneous and oral amycretin into phase 3 development for weight management [4] - REDEFINE 11 has been initiated to further investigate the efficacy and safety of CagriSema, and a higher dose of semaglutide has been submitted to EU regulatory authorities [4] Outlook - The sales growth outlook for 2025 is now expected to be 8-14% at constant exchange rates, with operating profit growth expected at 10-16% [4] - The lowered outlook is attributed to slower-than-expected market expansion and competition in the GLP-1 treatment space [4] Leadership Changes - Maziar Mike Doustdar will succeed Lars Fruergaard Jørgensen as president and CEO, effective 7 August 2025 [4] - The company will consolidate its research and development areas under Martin Holst Lange's leadership [4]

Nasdaq CopenhagenEuronext DublinLondon Stock Exchange Other stakeholders Date: 6 August 2025 Upward adjustment of expectations for 2025 Ringkjøbing Landbobank is upwardly adjusting its expectations for net profit for 2025. The expectations for net profit for the year are upwardly adjusted from the DKK 1,800 – 2,200 million range to the DKK 2,000 – 2,350 million range. The upward adjustment is based on a continued good credit quality and a loss and impairment level that has developed better than originally ...

Core Viewpoint - ABN AMRO has announced a share buyback programme with a total value of EUR 250 million aimed at reducing its share capital [1][2]. Group 1: Share Buyback Programme Details - The share buyback programme will commence on 7 August 2025 and is expected to conclude by December 2025 [2]. - The maximum number of shares to be repurchased will not exceed 10% of the issued shares, as authorized by the general meeting of shareholders on 23 April 2025 [1][3]. - The capital required for the buyback has been reserved and is excluded from the CET1 ratio of 14.8% reported at the end of Q2 2025 [2]. Group 2: Regulatory and Execution Aspects - The European Central Bank (ECB) has approved the share buyback programme, which will comply with the Market Abuse Regulation [3]. - NLFI will participate in the buyback in proportion to its current stake of 30.5% through off-market transactions [3]. - ABN AMRO has established a non-discretionary arrangement with a financial intermediary to conduct the buyback in the open market [4]. Group 3: Communication and Reporting - ABN AMRO will provide weekly updates on the progress of the share buyback programme through press releases and on its Investor Relations website [4].